Boston Scientific (NYSE:BSX) and Abbott (NYSE:ABT) subsidiary St. Jude Medical must face lawsuits brought by the University of California alleging that their ablation catheters infringe a pair of patents covering atrial fibrillation treatments. The university’s regents sued the companies last October (a similar suit was brought against AtriCure (NSDQ:ATRC) the next month, according to court documents), accusing the companies […]
stjudemedical
Medtronic looks to settle TAVR patent spat with doc inventor
Medtronic (NYSE:MDT) is looking to settle a patent infringement dispute over transcatheter aortic valve replacements with a doctor who sued the company and cross-town rival St. Jude Medical (NYSE:STJ), which last week lost its bid to have the case dismissed. Dr. Robert Snyder, founder of Snyders Heart Valve, filed suits last year in the U.S. District […]
HRS 2017 Roundup: Study pinpoints battery issue in Abbott’s Nanostim leadless pacer
A study of the Nanostim leadless pacemaker made by Abbott’s St. Jude Medical subsidiary pinpoints the cause of a battery depletion issue A study of the Nanostim leadless pacemaker Abbott acquired this year when it bought St. Jude Medical, presented last week at the annual Heart Rhythm Society conference, found that a battery depletion problem […]
Abbott wins CE Mark for new TactiCath ablation catheter
Abbott (NYSE:ABT) said today that the TactiCath sensor-enabled ablation catheter it bought along with St. Jude Medical (NYSE:STJ) this year won CE Mark approval in the European Union. The Chicago-area healthcare giant said the new TactiCath device can be integrated with another St. Jude product, the EnSite Precision heart mapping system it launched earlier this year. “The […]
Abbott wins CE Mark for Confirm Rx cardiac monitor
Abbott (NYSE:ABT) said today that its St. Jude Medical (NYSE:STJ) subsidiary won CE Mark approval in the European Union for the ConfirmRx insertable cardiac monitor, touting as the world’s 1st smartphone-compatible ICM. The continuous heart monitor is designed to work with St. Jude’s myMerlin mobile app to allow physicians to remotely follow patients and diagnose arrhythmias. Abbott said […]
FDA warns Abbott on St. Jude Medical plant in California
The FDA yesterday issued another warning letter about a St. Jude Medical (NYSE:STJ) plant in California, now owned by Abbott (NYSE:ABT), that makes cardiac rhythm management products. It’s at least the 2nd time the federal safety watchdog has flagged the plant in Sylmar, which makes defibrillators and the Merlin home cardiac monitor. In 2012 the FDA slapped St. […]
Study: Abbott’s CardioMEMS monitor performs better in real world than pivotal trial
Real-world results from patients with Abbott‘s (NYSE:ABT) CardioMEMS implantable heart monitor, which it acquired along with St Jude Medical in Jan., show greater reduction in pulmonary artery pressure than seen in the pivotal Champion clinical trial of the device, according to a new study. The study examined the 1st 2,000 patients implanted with the CardioMEMS device […]
Abbott floats bid to exchange St. Jude senior notes
Abbott (NYSE:ABT) said today it opened offers looking to exchange notes offered by St. Jude Medical, which it acquired for $25 billion last month, for notes issued by Abbott. Included are St Jude’s 2% senior notes due 2018, 2.8% senior notes due 2020, 3.25% senior notes due 2023, 3.875% senior notes due 2025 and 4.75% senior notes due 2043, […]
US Dept of Homeland Security updates on St Jude’s Merlin@home vulnerabilities
The US Department of Homeland Security this week published an updated advisory covering vulnerabilities associated with Abbott (NYSE:ABT) subsidiary St. Jude Medical’s Merlin@home devices. The agency warned that a vulnerability within the Merlin@home system could allow a third party to remotely “access or influence communications” between Merlin.net and transmitter endpoints, which could drain the battery or send […]
Abbott releases swath of BurstDR neuromod study data
Abbott (NYSE:ABT) this week released a wealth of new data on its neuromod technology, which it acquired in its $25 billion buy of St. Jude Medical (NYSE:STJ). Presentations included an analysis from the Sunburst study of St. Jude’s BurstDR technology, a sub-study of optimal BurstDR programming, an analysis of non-rechargeable spinal cord stimulation devices and a series of […]
Abbott launches St. Jude Medical’s Ensite Precision cardiac mapping
Abbott (NYSE:ABT) yesterday said it launched the EnSite Precision cardiac mapping system it acquired when it paid $25 billion for St. Jude Medical earlier this month. The commercial launch also included the sensor-enabled Advisor FL circular mapping catheter, Abbott said. The system, which won 510(k) clearance from the FDA in December 2016, was used for […]